Immunovant’s Batoclimab Excels in Clinical Trials for Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.
Image Credit: Adobe Stock Images/Lila Patel
Immunovant has shared positive results of its batoclimab in a Phase III clinical trial in myasthenia gravis (MG) and a Phase IIb trial in chronic inflammatory demyelinating polyneuropathy (CIDP).1
In the Phase III MG study, batoclimab demonstrated a meaningful change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) in AChR+ population at week 12, with a 5.6 point improvement in the higher dose arm and a 4.7 point improvement in the lower dose arm, meeting the primary endpoint.
Results from the Phase IIb trial in CIDP were from Period 1 following a standard of care washout. Data from the study show a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in patients who achieved an IgG lowering greater than 70%.
In a press release, Pete Salzmann, MD, chief executive officer of Immunovant, said: “We are excited to share positive results from our MG and CIDP studies. While neurologists and patients are very enthusiastic about currently approved FcRn inhibitors, they tell us that they also see a lot of potential for a next-generation FcRn inhibitor that can offer deeper and more durable responses for patients whose disease is still affecting their daily function.”
While results across both studies were positive, Immunovant stated it does not intend to seek regulatory approval for batoclimab in MG or CIDP. The company will wait to make a final decision on regulatory submissions for batolclimab until it receives results from Phase III studies evaluating the therapy in thyroid eye disease.
Salzmann continued: “Today’s results show that deeper IgG reduction leads to deeper responses in MG and CIDP. Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical outcomes - will apply to a wide range of auto-antibody mediated conditions.”
Immunovant also announced it has received clearance for its Investigational New Drug (IND) applications for its lead asset, IMVT-1402, in both MG and CIDP. The company will look to advance its IMVT-1402 program using data gathered from the batoclimab studies.
Reference
1. Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies. News release. Immunovant. March 19, 2025. Accessed March 19, 2025. https://www.immunovant.com/investors/news-events/press-releases/detail/71/immunovant-announces-positive-results-for-batoclimab
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase II DAHLIAS Trial Results Lead to Fast Track Designation for Nipocalimab for Sjögren’s Disease
March 18th 2025FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever approved for the autoimmune condition.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Merits of a Multifaceted Approach to Clinical Trial Recruitment
March 18th 2025According to a 2024 study “Benchmarking Site Activation and Patient Enrollment,” 33% of sites under-enrolled, and 14% failed to enroll a single patient. The best way to course-correct this is to adopt a multifaceted approach to patient recruitment, that goes beyond traditional channels and ways of thinking.
Bridging the Gap: How Chiesi Used External Collaboration to Get Closer to Patients
March 18th 2025Chiesi partnered with Citeline to enhance clinical trial awareness and patient engagement through its FREUD initiative by launching a Trial Portfolio Website, activating 150+ sites, and generating 600+ qualified referrals—learn more about how Citeline helped improve study discoverability, streamline recruitment, and strengthen Chiesi’s presence in key therapeutic areas.
